• Something wrong with this record ?

Identification of novel dithiocarbamate-copper complexes targeting p97/NPL4 pathway in cancer cells

M. Loffelmann, Z. Škrott, D. Majera, P. Štarha, V. Kryštof, M. Mistrík

. 2023 ; 261 (-) : 115790. [pub] 20230904

Language English Country France

Document type Journal Article

Dithiocarbamates (DTCs) are simple organic compounds with many applications in industry and medicine. They are potent metal chelators forming complexes with various metal ions, including copper. Recently, bis(diethyldithiocarbamate)-copper complex (CuET) has been identified as a metabolic product of the anti-alcoholic drug Antabuse (disulfiram, DSF), standing behind DSF's reported anticancer activity. Mechanistically, CuET in cells causes aggregation of NPL4 protein, an essential cofactor of the p97 segregase, an integral part of the ubiquitin-proteasome system. The malfunction of p97/NPL4 caused by CuET leads to proteotoxic stress accompanied by heat shock and unfolded protein responses and cancer cell death. However, it is not known whether the NPL4 inhibition is unique for CuET or whether it is shared with other dithiocarbamate-copper complexes. Thus, we tested 20 DTCs-copper complexes in this work for their ability to target and aggregate NPL4 protein. Surprisingly, we have found that certain potency against NPL4 is relatively common for structurally different DTCs-copper complexes, as thirteen compounds scored in the cellular NPL4 aggregation assay. These compounds also shared typical cellular phenotypes reported previously for CuET, including the NPL4/p97 proteins immobilization, accumulation of polyubiquitinated proteins, the unfolded protein, and the heat shock responses. Moreover, the active complexes were also toxic to cancer cells (the most potent in the nanomolar range), and we have found a strong positive correlation between NPL4 aggregation and cytotoxicity, confirming NPL4 as a relevant target. These results show the widespread potency of DTCs-copper complexes to target NPL4 with subsequent induction of lethal proteotoxic stress in cancer cells with implications for drug development.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000299
003      
CZ-PrNML
005      
20240213093046.0
007      
ta
008      
240109e20230904fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejmech.2023.115790 $2 doi
035    __
$a (PubMed)37690264
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Loffelmann, Martin $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 1333/5, Olomouc, 779 00, Czech Republic
245    10
$a Identification of novel dithiocarbamate-copper complexes targeting p97/NPL4 pathway in cancer cells / $c M. Loffelmann, Z. Škrott, D. Majera, P. Štarha, V. Kryštof, M. Mistrík
520    9_
$a Dithiocarbamates (DTCs) are simple organic compounds with many applications in industry and medicine. They are potent metal chelators forming complexes with various metal ions, including copper. Recently, bis(diethyldithiocarbamate)-copper complex (CuET) has been identified as a metabolic product of the anti-alcoholic drug Antabuse (disulfiram, DSF), standing behind DSF's reported anticancer activity. Mechanistically, CuET in cells causes aggregation of NPL4 protein, an essential cofactor of the p97 segregase, an integral part of the ubiquitin-proteasome system. The malfunction of p97/NPL4 caused by CuET leads to proteotoxic stress accompanied by heat shock and unfolded protein responses and cancer cell death. However, it is not known whether the NPL4 inhibition is unique for CuET or whether it is shared with other dithiocarbamate-copper complexes. Thus, we tested 20 DTCs-copper complexes in this work for their ability to target and aggregate NPL4 protein. Surprisingly, we have found that certain potency against NPL4 is relatively common for structurally different DTCs-copper complexes, as thirteen compounds scored in the cellular NPL4 aggregation assay. These compounds also shared typical cellular phenotypes reported previously for CuET, including the NPL4/p97 proteins immobilization, accumulation of polyubiquitinated proteins, the unfolded protein, and the heat shock responses. Moreover, the active complexes were also toxic to cancer cells (the most potent in the nanomolar range), and we have found a strong positive correlation between NPL4 aggregation and cytotoxicity, confirming NPL4 as a relevant target. These results show the widespread potency of DTCs-copper complexes to target NPL4 with subsequent induction of lethal proteotoxic stress in cancer cells with implications for drug development.
650    12
$a měď $x farmakologie $7 D003300
650    _2
$a proteiny $x metabolismus $7 D011506
650    _2
$a disulfiram $x farmakologie $7 D004221
650    _2
$a ubikvitin $x metabolismus $7 D025801
650    _2
$a proteasomový endopeptidasový komplex $7 D046988
650    12
$a nádory $x farmakoterapie $7 D009369
655    _2
$a časopisecké články $7 D016428
700    1_
$a Škrott, Zdeněk $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 1333/5, Olomouc, 779 00, Czech Republic
700    1_
$a Majera, Dušana $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 1333/5, Olomouc, 779 00, Czech Republic
700    1_
$a Štarha, Pavel $u Department of Inorganic Chemistry, Faculty of Science, Palacky University Olomouc, 17. listopadu 1192/12, Olomouc, 779 00, Czech Republic
700    1_
$a Kryštof, Vladimír $u Department of Experimental Biology, Faculty of Science, Palacky University Olomouc, Slechtitelu 27, Olomouc, 783 71, Czech Republic. Electronic address: vladimir.krystof@upol.cz
700    1_
$a Mistrík, Martin $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 1333/5, Olomouc, 779 00, Czech Republic. Electronic address: martin.mistrik@upol.cz
773    0_
$w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 261 (20230904), s. 115790
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37690264 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093043 $b ABA008
999    __
$a ok $b bmc $g 2049141 $s 1209993
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 261 $c - $d 115790 $e 20230904 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
LZP    __
$a Pubmed-20240109

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...